Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.1177/009885880903500103 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
The feasibility of implementing a digital pregnancy and postpartum support program in the Midwestern United States and the association with maternal and infant health.
Prev Med Rep
January 2025
Center for Advanced Practice, OSF HealthCare, Peoria, IL, USA.
Objective: The benefits of mobile applications in the prenatal period remain understudied. This study assessed associations between the Pregnancy Postpartum Support Program (PPSP), a digital wraparound service, and maternal and infant outcomes in a Medicaid population.
Methods: A retrospective analysis was conducted on pregnant patients with Medicaid insurance who received care and delivered in a Midwestern United States healthcare system between 8/1/2022-8/15/2023, comparing outcomes among those who did versus did not opt for PPSP enrollment.
DISCOntinuation of disease-modifying therapies in MS: The DISCOMS extension trial.
Mult Scler
January 2025
NYU MS Comprehensive Care Center, Department of Neurology, New York University Grossman School of Medicine, New York, NY, USA.
Background: In the DISCOMS (DISCOntinuation of disease-modifying therapies (DMTs) in multiple sclerosis (MS)) randomized clinical trial, we could not demonstrate that discontinuing MS DMTs in older, stable adults was not inferior to continuing DMTs. Relapses were rare in both groups, and most new disease activity was one to two new brain magnetic resonance imaging (MRI) lesions unassociated with clinical changes.
Objective/aims: Describe results of the DISCOMS extension study.
Validation of the Microlife BP3T01-1B blood pressure monitoring device in adults and adolescents according to the ISO 81060-2:2018 protocol.
Blood Press Monit
December 2024
Institute for Pharmacology and Preventive Medicine, Cloppenburg, Germany.
Background: Accurate measurement of blood pressure (BP) is crucial for the diagnosis and ongoing management of hypertension. Only devices that have been validated using an established protocol should be used to measure BP. The aim of this study was to validate the Microlife BP3T01-1B, an automated upper-arm BP measuring device, according to the DIN EN ISO 81060-2:2018-11 (ANSI/AAMI/ISO 81060-2:2018) standard protocol.
View Article and Find Full Text PDFEfficacy, safety, and quality of life of dabrafenib plus trametinib treatment in Chinese patients with mutation-positive metastatic non-small cell lung cancer.
Transl Lung Cancer Res
December 2024
Department of Medical Oncology, Sun Yat-sen University Cancer Center, State Key Laboratory of Oncology in South China, Guangdong Provincial Clinical Research Center for Cancer, Guangzhou, China.
Background: Dabrafenib plus trametinib (Dab + Tram) is an approved targeted therapy in patients with mutated metastatic non-small cell lung cancer (NSCLC). Here, we report the efficacy, safety, and quality of life (QoL) results of Dab + Tram treatment in Chinese patients with mutation-positive metastatic NSCLC.
Methods: This is a single-arm, open-label, multicentre, phase II study (NCT04452877).
Three-dimensional quantitative temporomandibular joint changes in skeletal class I malocclusion treated with extraction and non-extraction protocols: a comparative study of fixed orthodontic appliances and clear aligners.
Prog Orthod
January 2025
Department of Orthodontics, School and Hospital of Stomatology, China Medical University, Shenyang, 110002, P.R. China.
Objective: This study aimed to evaluate the positional and morphological changes in the temporomandibular joint (TMJ) in adult patients with skeletal Class I malocclusion treated with fixed orthodontic appliances (FAs) and clear aligners (CAs), both with and without premolar extractions.
Methods: This retrospective study involved 120 adult patients divided into non-extraction and extraction groups, each further subdivided equally into those treated with FAs and CAs. Cone beam computed tomography (CBCT) was used to assess the TMJ measurements before (T0) and after treatment (T1).
Want AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!